The subject of the tender is the conclusion of drug-related discount contracts according to Section 130a (8) SGB V on pharmaceuticals for up to 27 months from 01.01.2023 - 31.03.2025. The contracts relate to all contractual medicinal products that are delivered to the health insurance companies during the term of the contract. In principle, only prescription drugs are requested per lot. The call for tenders is generally carried out based on active ingredients within the meaning of Section 24b (2) AMG, not in the sense of Section 4 (19 AMG). 168 lots were formed. These are each subdivided into so-called exchange groups. DAK-G is authorized by the other replacement insurance companies to carry out the tender on behalf of and with effect for them. For more information, see the tender documents.

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the above lot, the intention is to establish discount contracts with up to 2 pharmaceutical entrepreneurs (as

individual bidders or as bidder association (s) of pharmaceutical companies).

In the case of the above lot, the intention is to establish discount contracts with up to 2 pharmaceutical entrepreneurs (as

individual bidders or as bidder association (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).